Connect Biopharma Surges After Positive COPD Trial Readout

Connect Biopharma Holdings Limited (CNTB) is up 34.3% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely driver is positive preliminary topline data from the company’s Phase 2 Seabreeze STAT COPD study of rademikibart. Investors appear to be responding to signs that the drug reduced treatment failure, cut new moderate-to-severe COPD exacerbations, and may now have a clearer path toward Phase 3 discussions with the FDA.

Details:

Connect Biopharma announced on September 30, 2026 that rademikibart reduced treatment failure versus placebo through one month by 81%, with statistical significance.

The same study showed an 85% reduction in new moderate-to-severe COPD exacerbations through one month, another result that was statistically significant.

The company also highlighted a 100% reduction in hospitalizations or emergency department visits for new acute COPD exacerbations in the study period, while saying the drug was well tolerated.

The readout follows positive asthma topline data disclosed on September 15, which may have reinforced investor confidence that rademikibart could support a broader late-stage development program in inflammatory lung disease.

Sources:

Connect Biopharma, SEC, GlobeNewswire

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$CNTB Hedge Fund Activity

We have seen 38 institutional investors add shares of $CNTB stock to their portfolio, and 16 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

BLACKROCK, INC. added 871,653 shares (+inf%) to their portfolio in Q2 2026, for an estimated $2,074,534
IKARIAN CAPITAL, LLC removed 849,952 shares (-15.8%) from their portfolio in Q2 2026, for an estimated $2,022,885
SILVERARC CAPITAL MANAGEMENT, LLC added 545,000 shares (+inf%) to their portfolio in Q2 2026, for an estimated $1,297,100
MILLENNIUM MANAGEMENT LLC removed 430,893 shares (-90.8%) from their portfolio in Q2 2026, for an estimated $1,025,525
683 CAPITAL MANAGEMENT, LLC added 385,000 shares (+42.8%) to their portfolio in Q2 2026, for an estimated $916,300
MARSHALL WACE, LLP added 269,629 shares (+408.4%) to their portfolio in Q2 2026, for an estimated $641,717
BOOTHBAY FUND MANAGEMENT, LLC removed 260,850 shares (-21.1%) from their portfolio in Q2 2026, for an estimated $620,823

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$CNTB Price Targets

Multiple analysts have issued price targets for $CNTB recently. We have seen 5 analysts offer price targets for $CNTB in the last 6 months, with a median target of $7.0.

Here are some recent targets:

Mazahir Alimohamed from Oppenheimer set a target price of $8.0 on 07/09/2026
Biren Amin from Piper Sandler set a target price of $7.0 on 06/26/2026
Brandon Folkes from HC Wainwright & Co. set a target price of $7.0 on 06/25/2026
Edward Nash from Canaccord Genuity set a target price of $6.0 on 05/26/2026
Olivia Brayer from Cantor Fitzgerald set a target price of $4.0 on 05/21/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.